BSR FEW II

Send

Brand: BSR

BSR FEW II is a clinical study that investigates the safety and efficacy of a novel Alzheimer's disease therapy called BAN0805 (also known as BAN2401) in participants who are in the early stages of the disease. FEW II is an extension study of a previous phase II clinical trial called FEW, which also evaluated the safety and efficacy of BAN0805. FEW II aims to continue treating participants who received BAN0805 during FEW for an additional 18 months and evaluate the long-term safety and efficacy of the treatment. It is being conducted by Biogen, a biotechnology company focused on developing treatments for neurodegenerative diseases, in collaboration with Eisai, Co. Ltd. And the BAN2401 investigators. Primary endpoints of the study include safety and tolerability of BAN0805, as well as changes in cognition and function over the course of the study. Secondary endpoints include changes in biomarkers of Alzheimer's disease, such as amyloid-beta and tau proteins. The study also includes an exploratory analysis of the impact of BAN0805 on brain connectivity and network topology using advanced neuroimaging techniques. Overall, FEW II is part of a larger clinical development program for BAN0805, known as Clarity, which includes both phase II and phase III trials. The goal of these trials is to evaluate the efficacy and safety of BAN0805 in individuals with mild cognitive impairment and mild Alzheimer's disease, as well as in patients with more advanced disease.